TB-500 — compound monograph
Acetylated heptapeptide fragment of thymosin beta-4. Unapproved, research supply. The Institute assesses 3 outcomes for this compound and grades the strongest at very low certainty.
§1Identification and status
§1.1Nomenclature
- Preferred name
- TB-500
- Compound class
- Acetylated heptapeptide fragment of thymosin beta-4
- Assessment series
- Repair and regeneration
- Synonyms and codes
- Ac-LKKTETQ · thymosin beta-4 fragment 17-23 (acetylated) · TB4 active fragment
- Route as evaluated
- Subcutaneous or intramuscular in research contexts
§1.2Chemistry
Chemical identifiers are reproduced where they are public. Where a structure has not been published the monograph records not disclosed rather than constructing one.[1]
- CAS registry number
- 885340-08-9
- Molecular formula
- C37H65N9O14
- Average mass
- 860.0
- Monoisotopic mass
- 859.46
- ATC classification
- not assigned
§1.3Sequence and structural notes
An N-acetylated heptapeptide corresponding to the actin-binding motif at residues 17–23 of thymosin beta-4. It is not thymosin beta-4 and the two are routinely conflated. Thymosin beta-4 is a 43-residue, 4963 Da protein; TB-500 is a 7-residue, 860 Da fragment. The Institute treats supply of one under the name of the other as an identity failure, and has recorded both directions of substitution in submitted third-party data.
§1.4Assessment status
The Institute assesses TB-500 across 3 indications and grades the strongest of them at very low certainty. Supplied as a research chemical; no marketing authorisation for the uses under which it is supplied.
Table 1. Assessed outcomes for TB-500, ordered by certainty. Each row links to the per-indication evidence extract.
| Indication | Effect as recorded | Certainty | Trials |
|---|---|---|---|
| Atherosclerotic cardiovascular disease and cardiovascular risk reduction | No randomised controlled human trial identified | Very low | 0 |
| Cutaneous wound healing and tissue repair | Clinical trials of the full-length thymosin beta-4 protein were conducted in epidermolysis bullosa and in dry-eye disease; results did not support… | Very low | 2 |
| Tendon, ligament and musculoskeletal soft-tissue injury | No randomised controlled human trial identified | Very low | 0 |
| Effects are reproduced as the contributing trials reported them. Where a confidence interval is held it appears on the per-indication extract rather than in this summary table. | |||
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH Harmonised Tripartite Guideline 1999;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.